[Combination cytostatic chemotherapy of advanced metastatic cancer of the prostate. A preliminary uncontrolled study].
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Cytostatisk kombinationskemoterapi af avanceret, metastaserende cancer prostatae. En foreløbig, ukontrolleret undersøgelse